In this webcast, experts discuss the SURTAVI trial and the SAPIEN 3 study in intermediate-risk patients as well as the outcomes of TAVR and SAVR.

Learn how transcatheter therapy can benefit patients that would not normally be candidates for TAVR and the importance of including the whole heart team for optimal success.

This webcast will discuss the options available to patients and give a comprehensive review of the data from the EXCEL and NOBLE trials. Conversations will also highlight some of the varied treatments currently used in Europe and what cardiac interventionists in the United States can anticipate.

During this informative webcast, listen to experts tackle the important topic of how best to revascularize patients with left main disease. Learn about data from the two main trials, EXCEL and NOBLE, in which patients with simple or moderate coronary artery disease with left main component are studied. Patients are compared randomly as either undergoing PCI or surgery.

This program will look at TAVR performance to have a clear understanding of the surgical risk strata identifying extreme, high, intermediate, and low risk patients. Throughout the discussion the participants will gain knowledge and tips on improving the selection for TAVR patients and the future of TAVR in low and intermediate risk patients.